Stock Analiz

Mimedx Group, Inc. MDXG

Medical/Dental Instruments · data as of November 13, 2026

$3.21Market cap $468M
Open the interactive analysis →

Mimedx Group, Inc. (MDXG) is a healthcare company listed in the US with a market value of about $468M. In the twelve months to September 30, 2026 it had revenue of $304M and net income of -$19M, a net margin of -6.3%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 26.2, 5-year revenue growth of 11% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.

About Mimedx Group

Mimedx Group is listed in the US and classified in medical/dental instruments. Revenue went from $118M in 2014 to $419M in 2025, growth of about 12.2% a year. It was profitable in 5 of the last 10 years in our data. Its share count rose by 33% over three years (dilution for shareholders). It spends 4% of revenue on research and development.

Score: 1.8 / 5

Value0/5
Future growth2/5
Track record2/5
Financial health5/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—
Forward P/E43.8
P/FCF26.2
P/S1.5
P/B2.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield3.8%
Shareholder yield0.0%
Intrinsic value vs. price−93%

Growth and quality

Revenue growth (1 yr)20.0%
Revenue growth (5 yrs, per year)11.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)5.3%
ROIC (5-yr avg.)1.8%
Profitable years (of last 10)5
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$304M$419M$349M$321M$268M$242M$248M$299M$359M$321M$245M
Net income-$19M$49M$42M$58M-$30M-$10M-$49M-$26M-$30M$65M$390000
Free cash flow$18M——$25M-$19M-$5M—————
EPS (diluted)$-0.13$0.32$0.28$0.37$-0.33$-0.15$-0.77$-0.24$-0.28$0.56$0.00
Net margin-6.3%11.6%12.2%18.1%-11.3%-4.2%-19.9%-8.6%-8.3%20.2%0.2%
ROIC—16.8%19.8%15.0%-32.5%-10.1%-67.3%-19.0%-6.2%49.5%1.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $7.00, 118% above the current price; targets range from $6.00 to $8.00; the consensus rating is “none”; expected EPS is $-0.09 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Mimedx Group stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Mimedx Group pay a dividend?

Not currently.

Is Mimedx Group a good stock to buy?

We do not give buy or sell advice. Mimedx Group scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.